Global Diagnostics And Therapeutics For Lung Cancer Market Size, Share 2022 : Brisk Insights

According to a recently published report, the Global Diagnostics and Therapeutics For Lung Cancer Market is expected to grow at the CAGR of 8% during 2015-2022. The global diagnostics and therapeutics for lung cancer market is segmented on the basis of drug type and geography. The report on Global Diagnostics and Therapeutics for Lung Cancer market forecast, 2012-2022 (by drug type, geography) provides detailed overview and predictive analysis of the market.

The global diagnostics and therapeutics for lung cancer market is expected to grow at the CAGR of 8% during 2015-2022. The global market is driven by increasing adoption of personalized treatments. Although new drugs have revitalized the lung cancer therapeutics market, patent expiry of existing drugs has posed a major threat to original drug manufacturers. NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies.

Browse Here For Full Report With ToC : http://www.briskinsights.com/report/diagnostics-and-therapeutics-for-lung-cancer-market

The market for diagnostics and therapeutics for lung cancer market is segmented as follows: by drug type and by geography. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market presently. The key players in the global diagnostics and therapeutics for lung cancer market include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.

Click Here For Same Category Reports : http://www.briskinsights.com/category/healthcare-market

Scope of the Report

Global diagnostics and therapeutics for lung cancer market by types of drugs, 2012 – 2022
1.1. Angiogenesis Inhibitor Market
1.2. EGFR Blockers Market
1.3. Kinase Inhibitor Market
1.4. Microtubule Stabilizer Market
1.5. Folate Antimetabolites Market
1.6. PD-1/PD-L1 Inhibitor Market
Global Diagnostics and Therapeutics for Lung Cancer market, regional outlook, 2012-2022 ($ BILLION)
2.1. North America
2.2. Europe
2.3. Asia Pacific
2.4. Middle East & Africa
2.5. Central & South America
Competitive Landscape
3.1. Astra Zeneca PLC
3.2. Boehringer Ingelheim
3.3. Bristol-Myers Squibb
3.4. Celgene Corporation
3.5. GlaxoSmithKline PLC
3.6. Eli Lilly & Co.
3.7. Pfizer, Inc.
3.8. Genentech, Inc. (a Roche company)
3.9. Sun Pharmaceutical Industries Ltd.3D Systems

Contact Us :

Jennifer Smith

Office 1094

109 Vernon House

Friar Lane

Nottingham

NG1 6DQ

United Kingdom

Phone : +448081890034 (UK)

Email : sales@briskinsights.com

Website : http://www.briskinsights.com/

About Us :

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.

Office 1094
109 Vernon House
Friar Lane
Nottingham

This release was published on openPR.